Celltrion to invest up to $478 mln to expand US factory in response to tariffs

Core Viewpoint - South Korean pharmaceutical company Celltrion plans to invest up to 700 billion Korean won ($478.17 million) to expand capacity at its U.S. factory in response to U.S. tariffs and rising demand [1] Company Summary - Celltrion is responding to U.S. tariffs by increasing its manufacturing capacity in the United States [1] - The investment of 700 billion Korean won is aimed at meeting the growing demand for its products [1] Industry Summary - The pharmaceutical industry is experiencing rising demand, prompting companies like Celltrion to expand their production capabilities [1] - U.S. tariffs are influencing foreign pharmaceutical companies to invest in local manufacturing to mitigate costs [1]